Cargando…
Exogenous stem cells pioneer a biobridge to the advantage of host brain cells following stroke: New insights for clinical applications
Stroke continues to maintain its status as one of the top causes of mortality within the United States. Currently, the only Food and Drug Administration (FDA)-approved drug in place for stroke patients, tissue plasminogen activator (tPA), has a rigid therapeutic window, closing at approximately 4.5...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057688/ https://www.ncbi.nlm.nih.gov/pubmed/30276314 http://dx.doi.org/10.4103/bc.bc_17_17 |